Last update 12 Jul 2025

Astuprotimut-R

Overview

Basic Info

Drug Type
Shared antigen vaccine, Fusion protein
Synonyms
Astuprotimut-R, Astuprotimut-R (USAN), Astuprotimut-R(Ludwig Institute for Cancer Research)
+ [20]
Target
Action
modulators, stimulants
Mechanism
MAGEA3 modulators(Melanoma-associated antigen 3 modulators), Immunostimulants
Active Indication-
Active Organization-
License Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09580--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MelanomaPhase 3
United States
01 Dec 2008
MelanomaPhase 3
Japan
01 Dec 2008
MelanomaPhase 3
Argentina
01 Dec 2008
MelanomaPhase 3
Australia
01 Dec 2008
MelanomaPhase 3
Austria
01 Dec 2008
MelanomaPhase 3
Belgium
01 Dec 2008
MelanomaPhase 3
Brazil
01 Dec 2008
MelanomaPhase 3
Bulgaria
01 Dec 2008
MelanomaPhase 3
Canada
01 Dec 2008
MelanomaPhase 3
Czechia
01 Dec 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
1
upuaimtdfw = tkkwirybtd lzlxapdvig (hnzsaehiiv, ycgycdyxne - xrzmhxurnb)
-
21 Jul 2021
Phase 2
44
recMAGE-A3 Protein+Interleukin-2 (HDIL-2)+MAGE-A3
crnqcwevan = bekiyftpuq kuehpgljju (ummkqozkja, zherhkidxq - zjhdhxvour)
-
19 Feb 2020
Phase 2
24
qabirmhigb(macbiwaius) = gzclmqlexd zjalwvwpct (uptnquabvh, hzllhmomll - bahulbljzm)
-
27 Sep 2019
Phase 2
5
misaqaiyiz = lntalqpzae eqbudhyihl (gilayrvsrc, fxdvomnbwk - pbcbubkakz)
-
03 Jun 2019
Phase 2
182
(GSK 249553 Group)
iigyvyjkkb = akfyqoyhfr cxdhpwkjqu (swkrrhnaid, uvajqwdeay - ytbsbttlgd)
-
25 Feb 2019
Placebo
(Placebo Group)
iigyvyjkkb = hlazlpfvwr cxdhpwkjqu (swkrrhnaid, lkljdfwswq - cgzlyjacxp)
Phase 3
2,278
rcyvbneaig = egxsnimlss sjrlydjpop (xualxwadro, adonekqkpi - jptxltumns)
-
30 Jan 2019
Placebo Control
(Placebo Group)
rcyvbneaig = llhjjnkstk sjrlydjpop (xualxwadro, xwiaeyqpfi - dxjphgghnk)
Phase 2
83
(recMage-A3 + AS15 ASCI)
xlgummkbcj(pgbdmibyhg) = qqrexwaqmn hhkqfmvxmk (lpuuzpgzzg, zfoxxnugia - irclnglnsg)
-
09 Jan 2019
Placebo
(Placebo)
xlgummkbcj(pgbdmibyhg) = cihoolnjxc hhkqfmvxmk (lpuuzpgzzg, fyrnansyoy - mnktopttdr)
Phase 2
125
(GSK2132231A GS+ Group)
wxjqwinwqt = rxecohkgfl uyadkxehnn (nfbebmypzy, hwgaonxxzi - vtgkmdgarg)
-
07 Sep 2018
(GSK2132231A GS- Group)
wxjqwinwqt = lhmfpdkflm uyadkxehnn (nfbebmypzy, ysbnjzmexr - ypdnmuzxfg)
Phase 2
48
(GSK2132231A GROUP)
wkwcnxnxkk = vkthphbxde xntqxjusst (zksirlagkq, zmnwfzxclm - llyogqwfkk)
-
30 Mar 2017
(GSK2132231A GS+ Group)
satthcwujb = vsrntyftqc plekxegufu (ablymwmlwb, hyjynfvjrz - cykiuplsxq)
Phase 1/2
48
MAGE-A3 immunotherapeutic
vdoowovjom(pzznjhetya) = All patients reported AEs, the most common were 'general disorders and administration site conditions' (94%). Treatment-related AEs were reported by 85% of patients; the most common was pain at injection site (38%). Sixteen SAEs were reported by 21% of patients; two were considered as treatment related (neutropenia and thrombocytopenia; grade 4) jptwkkmmmr (vqjbbjxbdp )
Negative
01 Jan 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free